Table 1 Baseline characteristics and therapy of the cohort
Characteristics | Entire cohort (n=28) |
|---|---|
Male, n (%) | 15 (53%) |
Age at HCT, median (range) | 25 (15–49) |
Stage at Dx, n (%) | |
  II | 7 (25) |
  III | 6 (21) |
  IV | 15 (54) |
Constitutional Symptoms at Dx, n (%) | 20 (71) |
Bulky Disease at Dx, n (%) | 8 (29) |
Front Line Treatment, n (%) | |
  ABVD | 23 (82) |
  ABVD → EscBEACOPP | 4 (14) |
  Other | 1 (4) |
IFRT, n (%) | 5 (18) |
Refractory (≤ 3 months remission), n (%) | 12 (43) |
Time to relapse, median months (range) | 7.9 (1.9–133) |
IGEV-Bv order of salvage, n (%) | |
  First | 14 (50) |
  Subsequent | 14 (50) |
No. of salvage cycles, median (range) | 2 (2–6) |
Number of cycles at stem cell collection, median (range) | 2 (1–5) |
Days of collection, median (range) | 1 (1–2) |
CD34x106/kg collected, median (range) | 13.6 (2.8–44.8) |
PET/CT status post IGEV-Bv, n (%) | |
  Complete metabolic response | 20 (71) |
  Partial metabolic response | 7 (25) |
  Stable disease | 1 (4) |
 Median follow-up, months (range) | 17 (0–65) |
